KeramidaKLazarosGNihoyannopoulosP. Right ventricular involvement in hypertrophic cardiomyopathy: patterns and implications. Hellenic J Cardiol. 2020;61(1):3-8. doi:10.1016/j.hjc.2018.11.009.
2.
MaronMSHauserTHDubrowE, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293-1298. doi:10.1016/j.amjcard.2007.05.061.
3.
MozaffarianDCaldwellJH. Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review. Clin Cardiol. 2001;24(1):2-8. doi:10.1002/clc.4960240102.
4.
SeoJHongYJKimYJ, et al. Prevalence, functional characteristics, and clinical significance of right ventricular involvement in patients with hypertrophic cardiomyopathy. Sci Rep. 2020;10(1):21908. doi:10.1038/s41598-020-78945-4.
5.
ArolaAJokinenERuuskanenO, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol. 1997;146(5):385-393. doi:10.1093/oxfordjournals.aje.a009291.
6.
ColanSDLipshultzSELoweAM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation. 2007;115(6):773-781. doi:10.1161/CIRCULATIONAHA.106.621185.
7.
LipshultzSESleeperLATowbinJA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647-1655. doi:10.1056/NEJMoa021715.
8.
NugentAWDaubeneyPEChondrosP, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639-1646. doi:10.1056/NEJMoa021737.
9.
NugentAWDaubeneyPEChondrosP, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation. 2005;112(9):1332-1338. doi:10.1161/CIRCULATIONAHA.104.530303.
10.
InglesJGoldsteinJThaxtonC, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12(2):e002460. doi:10.1161/CIRCGEN.119.002460.
11.
MaronBJMaronMSSemsarianC. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705-715. doi:10.1016/j.jacc.2012.02.068.
12.
RichardPCharronPCarrierL, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227-2232. doi:10.1161/01.CIR.0000066323.15244.54.
13.
BosJMWillMLGershBJKruisselbrinkTMOmmenSRAckermanMJ. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89(6):727-737. doi:10.1016/j.mayocp.2014.01.025.
LeeTMHsuDTKantorP, et al. Pediatric Cardiomyopathies. Circ Res. 2017;121(7):855-873. doi:10.1161/CIRCRESAHA.116.309386.
16.
AnanRNiimuraHTakenakaTHamasakiSTeiC. Mutations in the genes for sarcomeric proteins in Japanese patients with onset sporadic hypertrophic cardiomyopathy after age 40 years. Am J Cardiol. 2007;99(12):1750-1754. doi:10.1016/j.amjcard.2007.01.066.
17.
OmmenSRMitalSBurkeMA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020;142(25):e533-e557.
18.
FlynnJTKaelberDCBaker-SmithCM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. doi:10.1542/peds.2017-1904.
